PRESS RELEASE published on 06/13/2025 at 01:25, 1 year ago Moderna Receives U.S. FDA Approval for RSV Vaccine, mRESVIA, in Adults Aged 18–59 at Increased Risk for RSV Disease Moderna receives FDA approval to expand indication of mRESVIA vaccine for adults aged 18-59 at increased risk of RSV, based on Phase 3 study results showing safety and efficacy FDA Approval Moderna RSV Vaccine Phase 3 Study MRESVIA
BRIEF published on 06/11/2025 at 13:05, 1 year ago Moderna to Present at Barclays Science Call Series MRNA Technology Presentation Moderna Barclays Investor Event
BRIEF published on 06/11/2025 at 13:05, 1 year ago Moderna participera à la série d'appels scientifiques de Barclays Presentation Barclays Moderne Événement Pour Les Investisseurs Technologie De L'ARNm
PRESS RELEASE published on 06/11/2025 at 13:00, 1 year ago Moderna to Present at Upcoming Barclays Speaking the Science Call Series on June 16, 2025 Moderna, Inc. announces participation in Barclays Speaking the Science Call Series on June 16th at 10:00am ET. Webcast available on Moderna's website Webcast MRNA Medicine Moderna Barclays Investor Event
BRIEF published on 05/31/2025 at 06:21, 1 year ago Moderna's mNEXSPIKE COVID-19 Vaccine Secures FDA Approval FDA Approval COVID-19 Vaccine Clinical Trial Moderna MNEXSPIKE
BRIEF published on 05/31/2025 at 06:21, 1 year ago Le vaccin mNEXSPIKE de Moderna contre la COVID-19 obtient l'approbation de la FDA Essai Clinique Approbation De La FDA Moderne Vaccin Contre Le Covid-19 MNEXSPIKE
PRESS RELEASE published on 05/31/2025 at 06:16, 1 year ago Moderna Receives U.S. FDA Approval for COVID-19 Vaccine mNEXSPIKE Moderna's mNEXSPIKE, a new COVID-19 vaccine, receives FDA approval for high-risk age groups. The vaccine shows higher efficacy compared to the original mRNA-1273. Safety profile similar to Spikevax FDA Approval COVID-19 Vaccine Moderna Efficacy MNEXSPIKE
BRIEF published on 05/29/2025 at 00:05, 1 year 1 month ago Moderna Reports Progress and Setback in Avian Flu Vaccine Program Moderna Vaccine Development Phase 1/2 Study H5 Avian Flu MRNA-1018
BRIEF published on 05/29/2025 at 00:05, 1 year 1 month ago Moderna fait état de progrès et de revers dans son programme de vaccination contre la grippe aviaire Développement De Vaccins Moderne Étude De Phase 1/2 Grippe Aviaire H5 ARNm-1018
PRESS RELEASE published on 05/29/2025 at 00:00, 1 year 1 month ago Moderna Announces Update on Investigational Pandemic Influenza Program Moderna's Phase 1/2 H5 avian flu vaccine study shows positive interim results with robust immune response. HHS terminates late-stage development award Moderna Phase 1/2 Study Avian Flu Vaccine H5 Subtype HHS Termination
Published on 06/27/2026 at 16:50, 1 day 14 hours ago Redwood AI Announces Definitive Agreement with Quantum.IQ and Expands into Quantum Resistant Cyber Security
Published on 06/27/2026 at 01:40, 2 days 5 hours ago Polaris Renewable Energy Announces Results of Director Elections at Annual and Special Meeting
Published on 06/27/2026 at 00:00, 2 days 7 hours ago Onco-Innovations Initiates Three-Species Hepatocyte and Microsome Metabolism Studies for ONC010
Published on 06/26/2026 at 23:00, 2 days 8 hours ago Canadian North Resources Inc. Announces Results of 2026 Annual General and Special Shareholders Meeting
Published on 06/26/2026 at 22:50, 2 days 8 hours ago Banyan Gold Files Technical Report for AurMac Project, Yukon, Canada
Published on 06/29/2026 at 03:05, 3 hours 55 minutes ago Monport Launches Mid-Year Sale Across Europe with Discount on Laser Engravers and Exclusive Free Gifts
Published on 06/29/2026 at 02:30, 4 hours 30 minutes ago Growing Demand for Color Metal Engraving Drives Interest in Advanced Fiber Laser Technology
Published on 06/29/2026 at 02:15, 4 hours 45 minutes ago A 'founding father of fitness' - Les Mills Snr 1934 - 2026
Published on 06/29/2026 at 02:05, 4 hours 55 minutes ago WIRobotics Begins Building a Physical AI Development Ecosystem: The First Technology Release Features the ALLEX Simulation Model
Published on 06/28/2026 at 20:00, 11 hours ago CPI Property Group – Successful Hybrid Tender and New Issue
